BioSpace News Archive

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna will present at the H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 16, 2020 at 11:00 AM EDT

Neoleukin Therapeutics, Inc., “Neoleukin”, a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 16, 2020 at 9:30 a.m. Eastern Time.

Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that the Company will participate in a virtual fireside chat at the H.C. Wainwright 22nd Annual Global Investment Conference

Beyond Air, Inc. (NASDAQ: XAIR), today announced that two e-poster presentations have been accepted for the CHEST 2020 Annual Meeting, which is being held from October 18th to 21st.

Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) and the Sickle Cell Disease Association of America, Inc. (SCDAA) will host the 9th Annual Sickle Cell Disease (SCD) Therapeutics Conference on Tuesday, September 15.

Smith+Nephew, the global medical technology business, announces the launch of the HEALICOIL KNOTLESS Suture Anchor, expanding its revolutionary line of Advanced Healing Solutions for rotator cuff repair.

Datavant, the leader in helping healthcare organizations safely connect their data, today announced two agreements with Janssen Research & Development, LLC (Janssen R&D), to help link multiple real-world and clinical data sources with a goal to accelerate initiatives to build better medicines for patients.

MYOS RENS Technology, Inc. (“MYOS”) (NASDAQ: MYOS), “The Muscle Health Company” and owner of the advanced nutrition supplement Fortetropin®, announced today that it has hired The S3 Agency (S3)

Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a leader in science-based approaches to enhancing the quality and nutritional value of crops and food ingredients, announced today that it will be featured as a presenting company at the 22nd Annual Global Investment Conference sponsored by H.C Wainwright.

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it will present new research data for patritumab deruxtecan (U3-1402) and ENHERTU® (fam-trastuzumab deruxtecan-nxki), two of its lead DXd antibody drug conjugates (ADC), at the 2020 European Society of Medical Oncology (ESMO) Virtual Scientific Program to be held September 19-21, 2020 (#ESMO20).